Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2022-05-06 Share Issue/Capital Cha…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
Share Issue/Capital Change Classification · 95% confidence The document is a monthly return for movements in securities, specifically detailing movements in authorised/registered share capital and issued shares for the month ended 30 April 2022. It includes confirmations related to share issuance and compliance with listing rules. The document is submitted to the Hong Kong Exchanges and Clearing Limited and focuses on share capital and share movements without financial statements or earnings data. It is not an earnings release, annual or interim report, or a management discussion. It is a regulatory submission about share capital and share movements, fitting the category of Share Issue/Capital Change (SHA). The document length is 7165 characters, which is substantive and contains detailed data, not just an announcement or certification. Therefore, the best classification is SHA with high confidence.
2022-05-06 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 30 April 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 April 2022. It details movements in authorised/registered share capital, issued shares, and confirms compliance with listing rules. There is no financial performance data, earnings, or management discussion. The document is a regulatory submission about share capital and securities movements, typical of a regulatory filing to the stock exchange. It is not an annual or interim report, earnings release, or capital financing update. It fits best under Regulatory Filings (RNS) as a compliance and disclosure document related to share capital movements and confirmations to the exchange.
2022-05-06 English
DISCLOSEABLE TRANSACTION - PURCHASE OF WEALTH MANAGEMENT PRODUCTS
Capital/Financing Update Classification · 95% confidence The document is an announcement by RemeGen Co., Ltd. regarding the purchase of wealth management products using idle raised proceeds from an A Share Offering. It details the agreements with Qingdao Bank for structured deposit products, including terms, amounts, and dates. The document references Listing Rules and percentage ratios to determine discloseable transaction status. It is a disclosure of a financial transaction related to capital management and investment of raised proceeds, not a financial report, earnings release, or management discussion. The document is a formal announcement of a capital/financing update related to the company's use of funds from a share offering. It does not contain financial statements or earnings data, nor is it a regulatory filing or report publication announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-05-05 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 100% confidence The document lists the members of the board of directors and their roles and functions, including details about board committees. It does not contain financial data, earnings, or any report content. It is an announcement related to the company's board structure and management information. The document length is short (1514 characters), and it is clearly focused on board composition rather than a full report or announcement of voting results. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-05-05 English
POLL RESULTS OF THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results of the 2022 first extraordinary general meeting (EGM) of RemeGen Co., Ltd. It details the attendance, voting results, and changes in the board composition, specifically the appointment of a new independent non-executive director and the resignation of another. The document does not contain financial statements or detailed financial analysis but focuses on the voting outcomes and board changes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the results of shareholder votes at a general meeting and related board changes. The document length (5477 characters) and content confirm it is not merely a brief announcement or a report publication notice but a full declaration of voting results.
2022-05-05 English
UPDATES ON THE PUBLICATION OF ANNUAL REPORT
Report Publication Announcement Classification · 100% confidence The document is an announcement from Overseas Chinese Town (Asia) Holdings Limited regarding the expected publication date of their Annual Report for the year ended 31 December 2021. It references the completion of the auditing process and provides a timeline for the report's dispatch and publication. The document is short (2080 characters) and does not contain the actual annual report or substantive financial data, but rather informs shareholders and the public about the timing of the report's release. According to the 'MENU VS MEAL' rule, such announcements about report publication timing should be classified as Report Publication Announcement (RPA), not as the Annual Report (10-K).
2022-05-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.